What is autologous versus allogeneic cell therapy?

Autologous and allogeneic refer to two fundamentally different approaches to the source of cells used in a cellular therapy, and the distinction has significant implications for immune compatibility, manufacturing, and patient accessibility.

In an autologous cell therapy, the cells used to treat a patient are derived from that patient’s own body. In RMS’s case, this means taking cells from a patient with diabetes, reprogramming them into iPSCs, differentiating those iPSCs into Islet-Like Clusters, and transplanting the resulting ILCs back into the same patient. Because the cells carry the patient’s own genetic identity, the risk of immune rejection is significantly reduced, potentially eliminating the need for immunosuppressive drugs entirely.

In an allogeneic cell therapy, cells are derived from a donor source, typically a standardized cell line manufactured under Good Manufacturing Practice (GMP) conditions. Allogeneic approaches offer significant manufacturing and scalability advantages, as a single cell line can be used to treat many patients, but require strategies to manage immune compatibility. RMS is developing both approaches in parallel, recognizing that each has distinct advantages for different patient populations and clinical contexts.

Read about both approaches in RMS’s stem cell therapy program.